Raheleh Roudi

2.2k total citations
64 papers, 1.5k citations indexed

About

Raheleh Roudi is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Raheleh Roudi has authored 64 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 27 papers in Molecular Biology and 26 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Raheleh Roudi's work include Cancer Cells and Metastasis (17 papers), Lung Cancer Treatments and Mutations (12 papers) and Cancer Immunotherapy and Biomarkers (10 papers). Raheleh Roudi is often cited by papers focused on Cancer Cells and Metastasis (17 papers), Lung Cancer Treatments and Mutations (12 papers) and Cancer Immunotherapy and Biomarkers (10 papers). Raheleh Roudi collaborates with scholars based in Iran, United States and Italy. Raheleh Roudi's co-authors include Zahra Madjd, Ahmad Shariftabrizi, Alireza Korourian, Nicholas Syn, Navid Sobhani, Maryam Roudbary, Daniele Generali, Aram Davtyan, Yong Li and Giandomenico Roviello and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Scientific Reports.

In The Last Decade

Raheleh Roudi

62 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Raheleh Roudi Iran 24 868 620 442 330 314 64 1.5k
Wouter Hendrickx Qatar 24 1.0k 1.2× 570 0.9× 285 0.6× 495 1.5× 668 2.1× 59 1.9k
Ling Fu China 19 598 0.7× 559 0.9× 327 0.7× 256 0.8× 330 1.1× 59 1.5k
Briana G. Nixon United States 15 520 0.6× 502 0.8× 210 0.5× 204 0.6× 563 1.8× 18 1.3k
William C. Kisseberth United States 30 519 0.6× 863 1.4× 1.3k 3.0× 243 0.7× 388 1.2× 79 2.5k
Purnima Dubey United States 20 487 0.6× 556 0.9× 253 0.6× 141 0.4× 583 1.9× 45 1.5k
Yoichiro Moriya Japan 22 693 0.8× 364 0.6× 258 0.6× 157 0.5× 666 2.1× 49 1.6k
Ilaria Grazia Zizzari Italy 25 1.1k 1.2× 663 1.1× 315 0.7× 185 0.6× 782 2.5× 61 1.9k
Annie A. Wu United States 20 1.2k 1.4× 518 0.8× 134 0.3× 222 0.7× 1.1k 3.5× 35 2.0k
Ge Jin China 24 509 0.6× 1.2k 1.9× 112 0.3× 390 1.2× 382 1.2× 60 1.9k
Amy V. Paschall United States 18 468 0.5× 572 0.9× 104 0.2× 180 0.5× 506 1.6× 36 1.3k

Countries citing papers authored by Raheleh Roudi

Since Specialization
Citations

This map shows the geographic impact of Raheleh Roudi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raheleh Roudi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raheleh Roudi more than expected).

Fields of papers citing papers by Raheleh Roudi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raheleh Roudi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raheleh Roudi. The network helps show where Raheleh Roudi may publish in the future.

Co-authorship network of co-authors of Raheleh Roudi

This figure shows the co-authorship network connecting the top 25 collaborators of Raheleh Roudi. A scholar is included among the top collaborators of Raheleh Roudi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raheleh Roudi. Raheleh Roudi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sobhani, Navid, Alberto D’Angelo, Fernanda G. Kugeratski, et al.. (2025). Immune biomarkers for head and neck cancer. Cancer Immunology Immunotherapy. 75(1). 6–6. 1 indexed citations
2.
Roudi, Raheleh, et al.. (2025). CD47 as a potent target in cancer immunotherapy: A review. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1880(2). 189294–189294. 2 indexed citations
3.
D’Angelo, Alberto, et al.. (2024). Exploring the dichotomy of the mesenchymal stem cell secretome: Implications for tumor modulation via cell-signaling pathways. International Immunopharmacology. 143(Pt 1). 113265–113265. 1 indexed citations
4.
Roudi, Raheleh, et al.. (2024). Reproducibility and repeatability of quantitative T2 and T2* mapping of osteosarcomas in a mouse model. European Radiology Experimental. 8(1). 74–74.
5.
Sobhani, Navid, et al.. (2024). Patient-Derived Organoids: A Game-Changer in Personalized Cancer Medicine. Stem Cell Reviews and Reports. 21(1). 211–225. 6 indexed citations
6.
7.
8.
Roudi, Raheleh, et al.. (2023). Novel Clinically Translatable Iron Oxide Nanoparticle for Monitoring Anti-CD47 Cancer Immunotherapy. Investigative Radiology. 59(5). 391–403. 5 indexed citations
9.
Roviello, Giandomenico, Silvia Paola Corona, Michele Aieta, & Raheleh Roudi. (2019). Influence of Age and the Gleason Score in the Choice of Novel Hormonal Therapies Before and After Chemotherapy. Cancer Biotherapy and Radiopharmaceuticals. 34(3). 141–146. 2 indexed citations
10.
Roudi, Raheleh, Ata Abbasi, Maryam Abolhasani, et al.. (2019). High GD2 expression defines breast cancer cells with enhanced invasiveness. Experimental and Molecular Pathology. 109. 25–35. 29 indexed citations
11.
Korourian, Alireza, et al.. (2019). Induction of miR-31 causes increased sensitivity to 5-FU and decreased migration and cell invasion in gastric adenocarcinoma. Bratislavské lekárske listy/Bratislava medical journal. 120(1). 35–39. 17 indexed citations
12.
13.
Zanjani, Leili Saeednejad, Zahra Madjd, Arezoo Rasti, et al.. (2019). Spheroid-Derived Cells From Renal Adenocarcinoma Have Low Telomerase Activity and High Stem-Like and Invasive Characteristics. Frontiers in Oncology. 9. 1302–1302. 9 indexed citations
14.
Fathi, Zahra, Nicholas Syn, Jian‐Guo Zhou, & Raheleh Roudi. (2018). Molecular epidemiology of lung cancer in Iran: implications for drug development and cancer prevention. Journal of Human Genetics. 63(7). 783–794. 26 indexed citations
15.
Roudi, Raheleh, et al.. (2018). Association of homeobox B13 (HOXB13) gene variants with prostate cancer risk in an Iranian population. Medical Journal of the Islamic Republic of Iran. 32. 561–565. 6 indexed citations
16.
Kalantari, Elham, et al.. (2016). Increased Expression of ALDH1A1 in Prostate Cancer is Correlated With Tumor Aggressiveness: A Tissue Microarray Study of Iranian Patients. Applied immunohistochemistry & molecular morphology. 25(8). 592–598. 39 indexed citations
17.
Roudi, Raheleh, Elham Kalantari, Abbasali Keshtkar, & Zahra Madjd. (2016). Accuracy of c-KIT in lung cancer prognosis; a systematic review protocol" instead of c-KIT Expression in Lung Cancer Prognostic Evaluation - a Systematic Review Protocol. Asian Pacific Journal of Cancer Prevention. 17(2). 863–866. 1 indexed citations
18.
Roudi, Raheleh, et al.. (2016). Evaluation of anaplastic lymphoma kinase expression in nonsmall cell lung cancer; a tissue microarray analysis. Journal of Cancer Research and Therapeutics. 12(2). 1065–1069. 5 indexed citations
19.
Roudi, Raheleh, Zahra Madjd, Marzieh Ebrahimi, et al.. (2016). Evidence for embryonic stem-like signature and epithelial-mesenchymal transition features in the spheroid cells derived from lung adenocarcinoma. Tumor Biology. 37(9). 11843–11859. 21 indexed citations
20.
Roudi, Raheleh, Zahra Madjd, Marzieh Ebrahimi, Fazel Sahraneshin Samani, & Alí Samadikuchaksaraei. (2013). CD44 and CD24 cannot act as cancer stem cell markers in human lung adenocarcinoma cell line A549. Cellular & Molecular Biology Letters. 19(1). 23–36. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Wouter Hendrickx Breakdown of academic impact, for papers by Ling Fu Breakdown of academic impact, for papers by Briana G. Nixon Breakdown of academic impact, for papers by William C. Kisseberth Breakdown of academic impact, for papers by Purnima Dubey Breakdown of academic impact, for papers by Yoichiro Moriya Breakdown of academic impact, for papers by Ilaria Grazia Zizzari Breakdown of academic impact, for papers by Annie A. Wu Breakdown of academic impact, for papers by Ge Jin Breakdown of academic impact, for papers by Amy V. Paschall
Rankless by CCL
2026